This figure may underestimate the real frequency as it was thought that only around 50% of PCAWG tumors had sufficient coverage to call a mutation at the two TERT promoters (among the cohort with no known drivers, further analysis identified TERT mutations in six hepatocellular carcinomas and two biliary cholangiocarcinomas). Here, TERT is linked to hepatocellular carcinoma.